Tumor objective response was observed at dose levels of 1.0 mg/kg Q4W and above, with an objective response observed as best response in 48.4% (44/91) of patients with HER2-positive breast cancer across all these dose levels. This evidence concerns the gene ERBB2 and neoplasm.